MA27667A1 - Analogues de la prostaglandine comme antagonistes du recepteur de ep4 - Google Patents

Analogues de la prostaglandine comme antagonistes du recepteur de ep4

Info

Publication number
MA27667A1
MA27667A1 MA28497A MA28497A MA27667A1 MA 27667 A1 MA27667 A1 MA 27667A1 MA 28497 A MA28497 A MA 28497A MA 28497 A MA28497 A MA 28497A MA 27667 A1 MA27667 A1 MA 27667A1
Authority
MA
Morocco
Prior art keywords
receptor antagonists
prostaglandin analogs
prostaglandin
analogs
glaucoma
Prior art date
Application number
MA28497A
Other languages
English (en)
Inventor
Xavier Billot
John Colucci
Yongxin Han
Marie-Claire Wilson
Robert N Young
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of MA27667A1 publication Critical patent/MA27667A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

AGONISTE DU RECEPTEUR EP4, COMPOSITIONS ET METHODES POUR CELLES-LA Cette invention concerne des agonistes sélectifs puissants du sous-type EP4 des récepteurs E2 de la prostaglandine, leur usage ou une composition de ceux-là dans le traitement du glaucome et autres affections, qui sont liées à une pression intraoculaire élevée dans l'oeil d'un patient.
MA28497A 2003-03-26 2005-09-14 Analogues de la prostaglandine comme antagonistes du recepteur de ep4 MA27667A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45770003P 2003-03-26 2003-03-26

Publications (1)

Publication Number Publication Date
MA27667A1 true MA27667A1 (fr) 2005-12-01

Family

ID=33098243

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28497A MA27667A1 (fr) 2003-03-26 2005-09-14 Analogues de la prostaglandine comme antagonistes du recepteur de ep4

Country Status (22)

Country Link
US (4) US7053085B2 (fr)
EP (1) EP1613621B1 (fr)
JP (1) JP4866992B2 (fr)
KR (1) KR20060002873A (fr)
CN (1) CN1764659A (fr)
AR (1) AR040806A1 (fr)
AT (1) ATE474837T1 (fr)
BR (1) BRPI0408690A (fr)
CA (1) CA2519938C (fr)
CL (1) CL2004000655A1 (fr)
DE (1) DE602004028229D1 (fr)
EC (1) ECSP056037A (fr)
ES (1) ES2347434T3 (fr)
HR (1) HRP20050845A2 (fr)
IS (1) IS7999A (fr)
MA (1) MA27667A1 (fr)
MX (1) MXPA05010189A (fr)
NO (1) NO20054951L (fr)
PE (1) PE20050522A1 (fr)
RU (1) RU2005132930A (fr)
TW (1) TW200427670A (fr)
WO (2) WO2004085431A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
RU2311409C2 (ru) * 2003-01-10 2007-11-27 Ф.Хоффманн-Ля Рош Аг Производные 2-пиперидона в качестве агонистов простагландина
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
BRPI0411057A (pt) * 2003-06-06 2006-07-25 Allergan Inc análogos de prostaglandina e de piperidinila
US6977260B2 (en) 2004-01-22 2005-12-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7326716B2 (en) 2003-06-06 2008-02-05 Allergan, Inc. Treatment of inflammatory bowel disease
CN1845914A (zh) 2003-09-02 2006-10-11 默克公司 用于治疗眼压过高的眼用组合物
WO2005025568A1 (fr) 2003-09-04 2005-03-24 Merck & Co., Inc. Compositions ophtalmiques pour traiter l'hypertension oculaire
KR20060090801A (ko) 2003-09-04 2006-08-16 머크 앤드 캄파니 인코포레이티드 고안압증 치료용 안용 조성물
CA2571786A1 (fr) * 2004-07-02 2006-02-09 Allergan, Inc. Analogues de prostaglandine
CN1988903A (zh) * 2004-07-20 2007-06-27 默克公司 用于治疗高眼压症的眼用组合物
JP2008518013A (ja) * 2004-10-26 2008-05-29 アラーガン、インコーポレイテッド プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
WO2006052630A1 (fr) * 2004-11-04 2006-05-18 Allergan, Inc. Composes therapeutiques de piperidone substituee
EP1847533B1 (fr) * 2005-01-27 2013-08-14 Asahi Kasei Pharma Corporation Compose heterocyclique a six chainons et utilisation de celui-ci
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
EP1912957A4 (fr) * 2005-08-03 2009-05-13 Merck Frosst Canada Ltd Récepteur agoniste ep4, compositions et méthodes qui en découlent
EP1912977A4 (fr) * 2005-08-03 2009-10-21 Merck Frosst Canada Ltd Agoniste du recepteur ep4, compositions et procedes
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
US7550448B2 (en) * 2006-05-24 2009-06-23 Allergan, Inc. Therapeutic compounds
US7498447B2 (en) 2006-05-24 2009-03-03 Allergan, Inc. Therapeutic compounds
WO2008027341A2 (fr) * 2006-08-30 2008-03-06 Merck & Co., Inc. Formulations ophtalmiques locales
WO2008027340A2 (fr) * 2006-08-30 2008-03-06 Merck & Co., Inc. Formulations ophtalmiques locales
EP3824885A1 (fr) 2006-10-20 2021-05-26 Children's Medical Center Corporation Procédé pour améliorer la régénération tissulaire
CN101168514B (zh) * 2006-10-26 2011-12-07 上海药明康德新药开发有限公司 光学活性α-氨基辛二酸酯和α-氨基辛二酸单酯的合成方法
AU2007331471C1 (en) 2006-12-15 2013-07-25 Glaxo Group Limited Benzamide derivatives as EP4 receptor agonists
GB2446652A (en) * 2007-02-16 2008-08-20 Inion Ltd Osteogenic compounds
AU2008246579A1 (en) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
US20100179137A1 (en) * 2007-06-07 2010-07-15 Takashi Kamikubo Pyridone compound
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
CN101468985A (zh) * 2007-12-28 2009-07-01 中国人民解放军军事医学科学院毒物药物研究所 5-(3-芳杂环取代苯基)四氮唑类化合物及其抗hiv/aids的应用
US8633310B2 (en) 2008-02-19 2014-01-21 Allergan, Inc. Therapeutic substituted lactams
US7964596B2 (en) 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
WO2011047048A1 (fr) 2009-10-14 2011-04-21 Gemmus Pharma, Inc. Traitement par polythérapie pour infections virales
CA2738045C (fr) 2010-05-28 2019-02-19 Simon Fraser University Composes conjugues, leurs procedes de fabrication et leurs utilisations
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
CN107849072B (zh) 2015-06-12 2020-12-15 西蒙弗雷泽大学 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
WO2017126635A1 (fr) * 2016-01-22 2017-07-27 武田薬品工業株式会社 Composé hétérocyclique et utilisation de celui-ci
CN111511736B (zh) 2017-12-25 2023-03-24 旭化成制药株式会社 含氮6元环化合物
EP4706758A3 (fr) 2019-05-21 2026-05-06 Ardelyx, Inc. Procedes d'inhibition du transport de phosphate
CN111269193B (zh) * 2020-04-02 2022-05-24 湖南海利常德农药化工有限公司 一种苯并[e][1,3]噁嗪-2,4-二酮的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524818A (en) 1974-11-29 1978-09-13 Beecham Group Ltd 12-azaprostaglandins
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
EP0008186A1 (fr) 1978-08-08 1980-02-20 Beecham Group Plc Diamides cycliques, procédé pour leur préparation et leurs compositions pharmaceutiques
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) * 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
US4960771A (en) * 1988-07-12 1990-10-02 Rajadhyaksha Vithal J Oxazolidinone penetration enhancing compounds
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
WO1990002553A1 (fr) * 1988-09-06 1990-03-22 Pharmacia Ab Derives de prostaglandine servant au traitement des glaucomes ou de l'hypertension oculaire
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH10265454A (ja) 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
US6043275A (en) * 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
US6586468B1 (en) 1998-09-14 2003-07-01 Ono Pharmaceutical Co., Ltd. ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient
WO2000021542A1 (fr) 1998-10-15 2000-04-20 Merck & Co., Inc. Methodes de stimulation de la formation osseuse
AU2183900A (en) * 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
AP2001002357A0 (en) 1999-12-22 2001-12-31 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis.
PL358481A1 (en) 2000-03-17 2004-08-09 Alcon Inc. 6-hydroxy-indazole derivatives for treating glaucoma
WO2001072268A1 (fr) 2000-03-31 2001-10-04 Toray Industries, Inc. Agents de régulation de la pousse du cheveu ou de sa formation
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
PT1339678E (pt) 2000-11-27 2007-11-30 Pfizer Prod Inc Agonistas selectivos do receptor ep4 no tratamento de osteoporose
JP2004530647A (ja) 2001-01-30 2004-10-07 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧治療用眼薬組成物
EP1373545A4 (fr) 2001-03-22 2005-07-20 Merck & Co Inc Souris deficientes en mch1r
CA2466757A1 (fr) 2001-12-03 2003-06-12 Merck & Co., Inc. Methode de traitement de l'hypertension oculaire
US20040204590A1 (en) 2001-12-03 2004-10-14 Ogidigben Miller J. Ep4 receptor agonist, compositions and methods thereof
CA2488802A1 (fr) 2002-06-14 2003-12-24 Merck & Co., Inc. Compositions ophthalmiques pour traiter l'hypertension oculaire
JP2005538061A (ja) 2002-06-17 2005-12-15 メルク　エンド　カムパニー　インコーポレーテッド 新規ｍａｘｉ−ｋチャネルブロッカー、その使用方法および製造方法
AU2003247533B2 (en) 2002-06-17 2008-09-18 Merck & Co., Inc. Novel maxi-k channel blockers, methods of use and process for making the same
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
RU2311409C2 (ru) 2003-01-10 2007-11-27 Ф.Хоффманн-Ля Рош Аг Производные 2-пиперидона в качестве агонистов простагландина
US6747037B1 (en) * 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs

Also Published As

Publication number Publication date
ECSP056037A (es) 2006-01-27
CL2004000655A1 (es) 2005-01-21
RU2005132930A (ru) 2006-02-10
USRE42562E1 (en) 2011-07-19
CA2519938C (fr) 2010-11-30
NO20054951D0 (no) 2005-10-25
MXPA05010189A (es) 2006-02-22
CN1764659A (zh) 2006-04-26
CA2519938A1 (fr) 2004-10-07
AU2004224261A1 (en) 2004-10-07
JP4866992B2 (ja) 2012-02-01
WO2004085430A1 (fr) 2004-10-07
US7053085B2 (en) 2006-05-30
US20110237511A1 (en) 2011-09-29
EP1613621B1 (fr) 2010-07-21
ATE474837T1 (de) 2010-08-15
HRP20050845A2 (en) 2006-05-31
US7238710B2 (en) 2007-07-03
US20040198701A1 (en) 2004-10-07
BRPI0408690A (pt) 2006-03-28
EP1613621A1 (fr) 2006-01-11
DE602004028229D1 (de) 2010-09-02
IS7999A (is) 2005-08-25
AR040806A1 (es) 2005-04-20
PE20050522A1 (es) 2005-07-06
KR20060002873A (ko) 2006-01-09
JP2006520758A (ja) 2006-09-14
US20050227969A1 (en) 2005-10-13
TW200427670A (en) 2004-12-16
ES2347434T3 (es) 2010-10-29
WO2004085431A1 (fr) 2004-10-07
NO20054951L (no) 2005-12-22

Similar Documents

Publication Publication Date Title
MA27667A1 (fr) Analogues de la prostaglandine comme antagonistes du recepteur de ep4
ES2252978T3 (es) Agonistas 5ht2 serotonergicos para tratar el glaucoma.
NO20071660L (no) Nye pyridinonderivater og deres anvendelse som positive allosteriske modulatorer av MGLUR2-reseptorer
AR055050A1 (es) Composicion farmaceutica que comprende n-etil-9a, 11a, 15s- trihidoxi-17-fenil-18,19,20-trinor-prosta -5z, 13e- dien-1-amida (bimatoprost) y cloruro de benzalconio, y uso de estos compuestos par la preparacion de la misma
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
TNSN01166A1 (fr) Composes agonistes selectifs des recepteurs ep4 et compositions les contenant.
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
AU2011282681B2 (en) Preservative free bimatoprost and timolol solutions
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA33365B1 (fr) Dérivés de spiro[2.4]heptane pontés utiles en tant qu'agonistes du récepteur de alx et/ou du récepteur fprl2
MA28435B1 (fr) Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4
MA27428A1 (fr) Derives de pyrimidine et leur utilisation en tant que modulateurs cb2
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA31016B1 (fr) Composes de diazepan substitues comme antagonistes des recepteurs de l'orexine.
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
ATE464304T1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonist n
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
GEP20094780B (en) Prostaglandin nitrooxyderivatives
TN2009000028A1 (fr) Agonistes de ep2
RU2017139870A (ru) Новые агонисты npr-b
TN2009000112A1 (fr) Derives de sulfonamides servant d'agonistes adrenergiques et d'antagonistes muscariniques
DE60334905D1 (de) 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
MA30703B1 (fr) Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii.
MA28680B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.